Seropositivity rate, anti-spike antibody higher in Covishield than Covaxin: Study – News2IN
India

Seropositivity rate, anti-spike antibody higher in Covishield than Covaxin: Study

Seropositivity rate, anti-spike antibody higher in Covishield than Covaxin: Study
Written by news2in

NEW DELHI: A latest study has found that both vaccines, Covishield and Covaxin elicited good immune response after two doses, although seropositivity rates and median anti-spike antibody titre was significantly higher in Covishield as compared to Covaxin.
The study is titled, Antibody Response after Second-dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study published in MedRxiv.
The results found that among the 515 HCW (305 Male, 210 Female), 95.0 per cent showed seropositivity after two doses of both vaccines.
Of the 425 Covishield and 90 Covaxin recipients, 98.1 per cent and 80.0 per cent respectively, showed seropositivity.
However, both seropositivity rate and median (IQR) rise in anti-spike antibody was significantly higher in Covishield vs.
Covaxin recipient (98.1 vs.
80.0 per cent; 127.0 vs.
53 AU/mL; both p

About the author

news2in